Menu

Gene Drive–Equipped Mosquitoes Released into Lab Environment

The large-scale experiments aim to test how the technology would fare in the wild, if deployed to knock down populations of the pests.

Feb 20, 2019
Jef Akst

ABOVE: © ISTOCK.COM, RANPLETT

In early February, researchers at secure laboratory in Terni, Italy, began releasing hundreds of genetically engineered mosquitoes into an enclosure that mimics the natural environment, NPR reports. The insects carry what’s known as a gene drive, a deleterious sequence designed be inherited by most offspring to spread quickly through the population, and the scientists are looking for unforeseen consequences of the modification before deploying the engineered insects to fight malaria and other mosquito-borne diseases in Africa and elsewhere.

“This will really be a breakthrough experiment,” Ruth Müller, an entomologist who runs the Italian lab, tells NPR. “It’s a historic moment.”

The particular gene drive in this experiment involves an alteration to the doublesex gene that stops female mosquitoes from laying eggs and causes them to develop mouth parts more similar to males, such that they can’t bite. Female mosquitoes are the ones that spread disease when they feed on human blood. If the gene drive can successfully spread the doublesex mutation, it could theoretically crash entire populations. (The project is funded by the Bill & Melinda Gates Foundation, which also supports NPR.)

Without gene drive, an allele will be passed from generation to generation via traditional Mendelian genetics. But in a gene drive that spreads the allele to the homologous chromosome in the germline, all progeny will receive a copy. (See full infographic.)
THE SCIENTIST STAFF

The approach has already demonstrated success in the lab, but before it’s launched in the real world, researchers must fully evaluate the potential consequences. The recent releases into the large-scale enclosure—six, nine-foot-tall “cages” with features meant to recreate the natural environment—will test the risks that may occur in the wild. The researchers placed different ratios of gene-drive mosquitoes–to–unmodified mosquitoes in four of the cages, with the remaining two used as controls with only unmodified insects.

See “Study: Gene Drive Wipes Out Lab Mosquitoes

Each week, the team will collect thousands of eggs to see how the doublesex mutation is spreading. The researchers estimate that they should be able to tell if the gene drive is efficient and effective within a year. But it will still be at least five years from deploying the insects in the wild, Tony Nolan, a geneticist at Imperial College London who helped develop the mosquitoes, tells NPR. “[W]ere it to work,” he says, “this would be transformative.”

Read Nolan’s feature in The Scientist, “Using Gene Drives to Limit the Spread of Malaria.”

March 2019

Going Under

Dissecting the effects of anesthetics

Marketplace

Sponsored Product Updates

The Complex Biology of Macrophages: Origins, Functions, and Activation States
The Complex Biology of Macrophages: Origins, Functions, and Activation States
Download this poster from R&D Systems for a detailed overview of macrophage markers, functions, development, specialization, and activation!
A Guide to Measuring Drug-Target Residence Times with Biochemical Assays
A Guide to Measuring Drug-Target Residence Times with Biochemical Assays
Download this guide from BellBrook Labs to learn about how to use Transcreener® biochemical assays to measure drug-target residence times, complete with examples and case studies!
Beckman Coulter Life Sciences To Launch New Product Via Live Stream Event
Beckman Coulter Life Sciences To Launch New Product Via Live Stream Event
After visiting labs around the world to identify ways to advance its industry-leading cell counting technology, Beckman Coulter Life Sciences will host a live streaming event on March 26 at 10 a.m. EDT / 7 a.m. PDT to announce its latest product innovation.  
Cybrexa Therapeutics to Present First Data and Unveil Details for its alphalex™-PARP Inhibitor Lead Candidate CBX-11 at AACR Annual Meeting 2019
Cybrexa Therapeutics to Present First Data and Unveil Details for its alphalex™-PARP Inhibitor Lead Candidate CBX-11 at AACR Annual Meeting 2019
Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its alphalex™ tumor targeting platform, today announced that Vishwas Paralkar, PhD, Chief Scientific Officer of Cybrexa, will present the first set of preclinical data supporting its alphalex™-PARP inhibitor lead candidate, CBX-11, at the American Association for Cancer Research (AACR) Annual Meeting 2019, being held March 29 – April 3 in Atlanta, Georgia. At the meeting, the Company will unveil the FDA-approved poly ADP-ribose polymerase (PARP) inhibitor conjugated in CBX-11.